CORDIS
EU research results

CORDIS

English EN
A prime boost strategy for immunotherapy of breast and ovarian cancer

A prime boost strategy for immunotherapy of breast and ovarian cancer

Objective

This project aims to develop a protocol for effective immunotherapy of breast and ovarian cancer based on a prime boost strategy and the MUC1 antigen which is over-expressed and aberrantly glycosylated in 90% of these malignancies. The strategy will combine cDNA priming with a glycoprotein boost. Different cancer-associated glycoforms of MUC1 will be produced in CHO cells, wild type, and modified by transfection of specific glycosyl transferases. The glycoproteins will be purified, characterised and comparatively evaluated with MUC1 cDNA for efficacy in tumour rejection in mouse models. Chemo-enzymically synthesised MUC1 glycopeptides will be used to evaluate immune responses. Conditions for production to GMP standard of MUC1 cDNA and the selected glycoprotein will be established to prepare for a clinical study. The pattern of glycosylation in cancer cells will be defined with microarray technology and MUC1 cDNA modified.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

CANCER RESEARCH UK

Address

Lincoln'S Inn Field 61
Wc2a 3px London

United Kingdom

Administrative Contact

John TOY

Participants (7)

Sort alphabetically

Expand all

CANCER RESEARCH TECHNOLOGY LIMITED

United Kingdom

FORSCHUNGSZENTRUM JUELICH GMBH

Germany

GOETEBORG UNIVERSITY

Sweden

UNIVERSITY OF COPENHAGEN

Denmark

UNIVERSITY OF ROME "LA SAPIENZA"

Italy

UNIVERSITY OF UMEAA

Sweden

UNIVERSITY OF ZURICH

Switzerland

Project information

Grant agreement ID: QLK3-CT-2002-02010

  • Start date

    1 December 2002

  • End date

    31 March 2006

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 2 991 366

  • EU contribution

    € 2 170 818

Coordinated by:

CANCER RESEARCH UK

United Kingdom